Ferring Pharmaceuticals and Gene Security Network (GSN) announced that they have signed an agreement to conduct a clinical trial of GSN’s advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™. The 11-center U.S. trial is designed to evaluate if GSN’s PGD technology helps increase in vitro fertilization (IVF) success rates when using single cell embryo testing for an abnormal number of chromosomes, a condition called aneuploidy…

More: 
Ferring Pharmaceuticals And Gene Security Network Partner To Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology

You may also like:

• Kinex Pharmaceuticals Initiates A Phase 2 Clinical Trial Of KX2-391 In Patients With Prostate Cancer
• Pieris Initiates Phase I Clinical Trial For Lead Anticalin Compound
• New Heart Ultrasound Research Shows Promise For Diagnosing And Treating Nation’s #1 Killer
• Three Rivers Announces Positive Results From Phase 3 DIRECT Trial Of Once-Daily INFERGEN(R) With Ribavirin In Hepatitis C Virus Treatment Failures
• Families With Rare Forms Of Diabetes Gather To Celebrate Progress
• Artificial Pancreas Can Prevent The Development Of Hypoglycemia
• FDA Advisory Committee Unanimously Recommends Approval Of HRA Pharma’s Ulipristal Acetate For Emergency Contraception
• ARIKACE™ Demonstrates Sustained Benefit In The Treatment Of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
• Amylin Pharmaceuticals To Present New Data And Insights From The Company’s Diabetes Programs At ADA 2010
• Patient Safety, Medical Liability Project Funded By $3 Million Grant To UIC